Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA In Brief

This article was originally published in The Gray Sheet

Executive Summary

Clinical literature guidance: FDA is considering a collaboration with the National Institutes of Health and the Centers for Medicare & Medicaid Services on a guidance aimed at the use of literature to support claims. The device center and industry had been working on a genetic testing guidance addressing the use of literature in lieu of prospective trials (1"The Gray Sheet" Sept. 3, 2001, p. 8). That effort is currently "stalled," according to CDRH Division of Clinical Laboratory Devices Director Steven Gutman, who notes, however, that it could be revived via HHS intra-departmental collaboration. "NIH is interested in looking at use of clinical literature, and CMS is interested in looking at clinical literature. We are being instructed by [HHS Secretary] Tommy Thompson to behave as one department and try and actually be consistent across agencies," the DCLD director reports at the Association of Medical Diagnostics Manufacturers annual meeting...

You may also be interested in...



Whole-Body CT Scans, Cancer Screening Enjoy Positive Public Image – JAMA

The U.S. public's apparent zeal for early cancer screening tests such as whole-body CT scans should be tempered with an understanding of the "risk for overtesting and overtreatment," the authors of a study in the Jan. 7 Journal of the American Medical Association conclude

Whole-Body CT Scans, Cancer Screening Enjoy Positive Public Image – JAMA

The U.S. public's apparent zeal for early cancer screening tests such as whole-body CT scans should be tempered with an understanding of the "risk for overtesting and overtreatment," the authors of a study in the Jan. 7 Journal of the American Medical Association conclude

CTA, MRA Aneurysm Screening Technologies Appraised By Neuroradiologists

Computed tomography angiography (CTA) will likely supplant traditional x-ray angiography as the basis for decisions on treating sub-arachnoid aneurysms, according to Joseph Heiserman, MD, Barrow Neurological Institute, Phoenix

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016503

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel